TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
ARGX

argenx NV

Healthcare · Biotechnology

960.00$ -2.2% vs. previous close Closing price · As of: Nov 13, 2026

Statements

Income Statement

argenx NV (ARGX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q3 26), "Revenue" came in at 1,721 million EUR. Tick rows to compare them in a chart.

All figures in millions of EUR.

Tick rows to compare them in a chart (up to 4)

Income Statement ARGX
Line item Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 LTM
401 401 573 573 1,346 791 948 1,127 3,206 1,298 2,816 1,721 9,040
43 43 59 59 665 81 111 109 340 121 279 165 905
358 358 514 514 681 710 837 1,018 2,866 1,177 2,536 1,556 8,135
225 225 236 236 297 309 328 359 443 443 486 503 1,875
199 236 341 278 257 276 423 336 423 355 533 598 1,908
451 451 500 500 563 569 633 780 2,015 904 1,690 1,071 5,679
-93 -93 14 14 117 141 204 347 851 394 847 485 2,577
0.5 0.5 0.7 0.7 0.7 1.1 1.1 1.0 1.0 1.0 2.0 1.0 5.0
-74 -74 88 88 175 202 287 386 992 426 959 538 2,915
-13 -13 -3.4 -3.4 33 33 42 – -55 – 119 32 –
-62 -62 91 91 866 169 245 344 1,047 366 839 506 2,758
-65 -65 98 98 127 203 301 387 1,009 427 864 539 2,839

LTM = last twelve months (sum of the four most recent quarters).

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?